A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,900 shares of CABA stock, worth $85,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,900
Previous 74,000 74.46%
Holding current value
$85,239
Previous $1.26 Million 88.83%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.22 - $18.82 $2.29 Million - $5.97 Million
317,305 Added 14159.08%
319,546 $2.39 Million
Q1 2024

May 15, 2024

SELL
$16.79 - $25.38 $531,218 - $802,997
-31,639 Reduced 93.39%
2,241 $38,000
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $383,601 - $733,901
31,417 Added 1275.56%
33,880 $769,000
Q3 2023

Nov 14, 2023

BUY
$11.84 - $18.65 $29,161 - $45,934
2,463 New
2,463 $37,000
Q1 2023

May 15, 2023

SELL
$7.08 - $12.62 $368,025 - $656,000
-51,981 Reduced 71.03%
21,197 $175,000
Q4 2022

Feb 14, 2023

BUY
$0.64 - $9.3 $46,833 - $680,555
73,178 New
73,178 $676,000
Q2 2022

Aug 15, 2022

SELL
$0.99 - $2.11 $218,414 - $465,510
-220,621 Reduced 14.96%
1,254,479 $1.33 Million
Q1 2022

May 16, 2022

SELL
$1.68 - $3.92 $41,198 - $96,130
-24,523 Reduced 1.64%
1,475,100 $2.99 Million
Q4 2021

Feb 14, 2022

BUY
$3.36 - $14.64 $3.16 Million - $13.8 Million
940,156 Added 168.04%
1,499,623 $5.68 Million
Q3 2021

Nov 15, 2021

BUY
$7.0 - $12.5 $3.65 Million - $6.53 Million
522,135 Added 1398.63%
559,467 $6.8 Million
Q2 2021

Aug 16, 2021

BUY
$7.2 - $11.73 $133,063 - $216,782
18,481 Added 98.04%
37,332 $321,000
Q1 2021

May 17, 2021

BUY
$10.39 - $14.53 $83,556 - $116,850
8,042 Added 74.4%
18,851 $209,000
Q4 2020

Feb 16, 2021

BUY
$9.81 - $15.8 $106,036 - $170,782
10,809 New
10,809 $135,000
Q2 2020

Aug 14, 2020

SELL
$6.39 - $11.28 $104,233 - $183,999
-16,312 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$6.0 - $18.67 $97,872 - $304,545
16,312 New
16,312 $119,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $131M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.